SitemapImprintDatenschutzerklärungdeutschenglish
MHH Logo

DIGIT HF

 

 

DIGIT HF is a study about therapy of heart insufficiency, which is funded by the Bundesministerium für Bildung und Forschung (BMBF). In the study will be investigated if the drug Digoxin, which increases the contractility of the heart, can prolong the lives of patients with a particular form of heart failure and reduce their hospital stays. Digitoxin belongs to the group of digitalis componends that - originally derived from the foxglove - can be used in selected patients for the treatment of heart failure or cardiac arrhythmia.

 

Patients:

  • 2.200 patients from 40 clinical sites

 

Samples:

  • Sera
  • Plasma